Illumina Files Two Patent Infringement Suits in Europe for Infringement of Patents for NIPT
January 07 2016 - 4:05PM
Business Wire
Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed
two patent infringement suits in Europe. The patents asserted use
cell-free fetal DNA for non-invasive prenatal testing (NIPT).
The first suit was filed against The Doctors Laboratory Ltd, TDL
Genetics Ltd, and Ariosa Diagnostics, Inc. in the High Court of
Justice, Chancery Division in the United Kingdom. The suit accuses
The Doctors Laboratory and TDL Genetics’ use of the Harmony™ NIPT
test supplied by Ariosa of infringing European Patent 0 994
963.
The second suit was filed against Centrum Badań Sp z o.o. and
Medgenetix Sp z o.o. in the Regional Court in Warsaw, Poland. The
suit accuses Centrum and Medgenetix’s use of the Iona® NIPT test
supplied by Premaitha Health PLC of infringing European Patent 2
183 693.
Illumina is seeking all available remedies, including damages
and injunctive relief.
These new lawsuits follow suits previously filed against Ariosa
in the United States and Premaitha in the United Kingdom.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160107006103/en/
Illumina, Inc.Investors:Rebecca
Chambers858-255-5243rchambers@illumina.comorMedia:Jennifer
Temple858-882-6822pr@illumina.comorDavid Robertson, Europe, Middle
East and Africa+44 1223 824909drobertson@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024